FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC By Ogkologos - November 27, 2025 83 0 Facebook Twitter Google+ Pinterest WhatsApp It also approved a companion diagnostic device to aid in detecting HER2 tyrosine kinase domain activating mutations Source RELATED ARTICLESMORE FROM AUTHOR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept MOST POPULAR ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung... June 4, 2023 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 Immunotherapy for Breast Cancer Treatment: Is It an Option? September 21, 2020 “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... June 8, 2021 Load more HOT NEWS Searching for novel connections in cancer metabolism Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following... Unusual or Nonreportable Results from Prenatal cfDNA-Sequencing Suggestive for an Occult... Bra Straps with Disappearing Message Remind Women to Check Their Breasts...
